About 50% of melanomas carry activating mutations in the BRAF oncogene and about 30% in the NRAS gene leading to overactivation of the mitogen-activated protein kinase (MAPK) pathway, making this signaling cascade a preferential target for melanoma treatment [8]. This evidence concerns the gene BRAF and melanoma.